biostudies-literature00390Unknown8(6)DeCensi A<h4>Objectives</h4>To assess Italian medical oncologists' opinion on the implications of conflict of interest (COI) on medical education, care and research, and to evaluate their direct financial relationships.<h4>Design</h4>National cross-sectional survey conducted between March and April 2017 among Italian oncologists.<h4>Setting</h4>Online survey sponsored by the Italian College of Medical Oncology Chiefs through its website.<h4>Participants</h4>Italian oncologists who filled out an anonymous questionnaire including 19 items and individual and working characteristics.<h4>Main outcome measure</h4>The proportion of medical oncologists perceiving COI as an outstanding issue and those receiving direct payments from industry.<h4>Results</h4>There were 321 respondents, representing 13% of Italian tenured medical oncologists. Overall, 62% declared direct payments from the pharmaceutical industry in the last 3 years. Sixty-eight per cent felt the majority of Italian oncologists have a COI with industry, but 59% suppose this is not greater than that of other specialties. Eighty-two per cent consider that most oncology education is supported by industry. More than 75% believe that current allocation of industry budget on marketing and promotion rather than research and development is unfair, but 75% consider it appropriate to receive travel and lodging hospitality from industry. A median net profit margin of €5000 per patient enrolled in an industry trial was considered appropriate for the employee institution. Sixty per cent agree to receive a personal fee for patients enrolled in industry trials, but 79% state this should be reported in the informed consent. Over 90% believe that scientific societies should publish a financial report of industry support. Finally, 79% disagree to being a coauthor of an article written by a medical writer when no substantial scientific contribution is made.<h4>Conclusions</h4>Among Italian oncologists COI is perceived as an important issue influencing costs, education, care and science. A more rigorous policy on COI should be implemented.BMJ opene020912https://www.ebi.ac.uk/biostudies/studies/S-EPMC6042593biostudies-literatureConflict of interest among Italian medical oncologists: a national survey.PMC6042593DeCensi ALivellara VRoila FRuggeri BTomirotti MWebber TBVerusio CBrandt KClerico MItalian College of Chief Medical Oncologists (CIPOMO)Giua CArtioli FNumico GFioretto LBallatori E39falseConflict of interest among Italian medical oncologists: a national survey.<h4>Objectives</h4>To assess Italian medical oncologists' opinion on the implications of conflict of interest (COI) on medical education, care and research, and to evaluate their direct financial relationships.<h4>Design</h4>National cross-sectional survey conducted between March and April 2017 among Italian oncologists.<h4>Setting</h4>Online survey sponsored by the Italian College of Medical Oncology Chiefs through its website.<h4>Participants</h4>Italian oncologists who filled out an anonymous questionnaire including 19 items and individual and working characteristics.<h4>Main outcome measure</h4>The proportion of medical oncologists perceiving COI as an outstanding issue and those receiving direct payments from industry.<h4>Results</h4>There were 321 respondents, representing 13% of Italian tenured medical oncologists. Overall, 62% declared direct payments from the pharmaceutical industry in the last 3 years. Sixty-eight per cent felt the majority of Italian oncologists have a COI with industry, but 59% suppose this is not greater than that of other specialties. Eighty-two per cent consider that most oncology education is supported by industry. More than 75% believe that current allocation of industry budget on marketing and promotion rather than research and development is unfair, but 75% consider it appropriate to receive travel and lodging hospitality from industry. A median net profit margin of €5000 per patient enrolled in an industry trial was considered appropriate for the employee institution. Sixty per cent agree to receive a personal fee for patients enrolled in industry trials, but 79% state this should be reported in the informed consent. Over 90% believe that scientific societies should publish a financial report of industry support. Finally, 79% disagree to being a coauthor of an article written by a medical writer when no substantial scientific contribution is made.<h4>Conclusions</h4>Among Italian oncologists COI is perceived as an important issue influencing costs, education, care and science. A more rigorous policy on COI should be implemented.2018-01-01T00:00:00Z2018 Jun2024-12-03T15:55:57.38Z2019-03-26T23:46:40ZS-EPMC60425932996101910.1136/bmjopen-2017-020912